Latest news

Thumbnail image for Allergan announces job cull to cut costs

Allergan announces job cull to cut costs

Allergan has unveiled plans to trim more than 1,000 jobs from its workforce in a bid to reduce costs and prepare for increased generic competition this year.

4th January 2018

Thumbnail image for CQC to rate health websites and non-NHS services

CQC to rate health websites and non-NHS services

The Care Quality Commission is to get new powers to award quality ratings to wider range of healthcare services, including websites for medical advice and prescriptions from GPs online.

4th January 2018

Thumbnail image for PIM status for Boehringer’s mesothelioma drug

PIM status for Boehringer’s mesothelioma drug

Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.

4th January 2018

Thumbnail image for NHS hospitals advised to delay non-urgent care

NHS hospitals advised to delay non-urgent care

NHS England is advising hospitals to defer non-urgent, elective operations and procedures until next month to help the health service deal with high pressures over the winter period.

3rd January 2018

Thumbnail image for NICE publishes final draft guidelines backing GSK’s Strimvelis

NICE publishes final draft guidelines backing GSK’s Strimvelis

Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.

3rd January 2018

Thumbnail image for GW’s cannabinoid Epidiolex under EU, US review

GW’s cannabinoid Epidiolex under EU, US review

Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.

2nd January 2018

Thumbnail image for Roche to buy Ignyta for $1.7 billion

Roche to buy Ignyta for $1.7 billion

Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.

2nd January 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download